ClinicalTrials.gg
RecruitingNCT07731295iPAWSUpdated Jul 28, 2026

iPAWS: Improving Pain Management After Wisdom Tooth Extraction Surgery

An interventional study of iPAWS and Educational Materials in Pain, Postoperative and Substance Use, sponsored by Brown University. Recruiting at 1 site in United States. Open to participants aged 15 Years to 20 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Brown University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
15 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,181 studies in Pain, Postoperative with a site in United States — 204 open to participants now, 237 under way, 25 of them phase 3. Pain, Postoperative · United States.

Planned enrollment
236th of 1,099
150 · median 76
Started
2026
with 67 others
No phase
373 of 1,181
68 open now
Primary completion
2026-12
later than 80 of 236 live
Registered
1,156th of 1,181
by date

Among the 1,181 studies in Pain, Postoperative with a site in United States, this one is the 236th largest by planned enrollment of the 1,099 interventional ones that give a count, is one of 68 that started in 2026, is one of 373 with no phase, reaches primary completion later than 80 of the 236 other live ones, and was the 1,156th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

204 of the 1,181 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:

198 more — sign in →

All 204 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 15 Years to 20 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,181 studies in Pain, Postoperative with a site in United States, or all of them as a file.
02

Study summary

This is a clinical trial that will evaluate the feasibility and acceptability of a virtual brief program for adolescents and young adults undergoing wisdom tooth extraction and their parents. The program aims to teach youth safe and effective ways to manage post-surgical pain as well as decrease risky health behaviors.

03

Conditions studied

  • Pain, Postoperative
  • Substance Use
04

Who can participate

Ages eligible
15 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 15 to 20 years
  • Undergoing wisdom tooth extraction for the first time
  • Able to read simple English
  • *Endorse cannabis use at least two days per week on average in the past 28 days

    *The investigator aims to recruit at least 50 participants who are using cannabis at least two days per week in the past 28 days on average and will recruit up to 100 additional participants who use other substances, use cannabis at a lesser intensity, or do not use any substances.

  • (Parent/Guardian only) - Have a child who is undergoing wisdom tooth surgery and is participating in the study

Exclusion criteria

Exclusion Criteria:

- N/A

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    iPAWS Intervention

    Participants in the experimental condition will receive standard practice educational materials and the iPAWS self-guided, digital intervention.

    Behavioral: iPAWS · Other: Educational Materials

  • Active comparator
    Educational Materials

    Participants in the control condition will receive standard practice educational materials (i.e., in the form of a brochure).

    Other: Educational Materials

Interventions

  • BehavioraliPAWS

    The brief intervention (named iPAWS) will be an integration of evidence-based brief interventions for AYA SU (e.g. MET-CBT) and acute pain coping (CBT). The intervention is brief, readily accessible, developmentally tailored, applicable to single and poly-SU and scalable to other acutely painful procedures to meet the need for effective, accessible, and scalable SU interventions at key entry points of clinical care.

  • OtherEducational Materials

    Participants will be given a digital copy of a brochure from the American Dental Association on "Wisdom Teeth Management" (included in attachments). The investigator will also mail the participant a hard copy of the brochure, if requested.

06

What researchers measure

Primary outcomes

  1. Number of participants who complete the active treatment phase (feasibility)

    The number of participants who complete the active treatment phase will determine feasibility. The treatment will be considered feasible if the number of participants who complete treatment is ≥ 70%.

    Time frame: End of active treatment phase (6 weeks)

  2. Number of participants who rate their treatment experience in the "satisfactory" or "highly satisfactory" range on the Client Satisfaction Questionnaire (Acceptability)

    The Client Satisfaction Questionnaire (CSQ-8) which ranges in scores from 8 to 32 will determine acceptability. Higher scores indicate higher satisfaction (i.e. better outcomes). Treatment will be considered acceptable if the number and percentage of participants who rate their experience either "satisfactory" or "highly satisfactory is ≥ 80%.

    Time frame: End of active treatment phase (6 weeks)

Secondary outcomes

  1. Number of cannabis use days

    Number of days that participants consumed cannabis over the last 3 weeks (weeks 4-6 of treatment) will be measured by the Timeline Followback Interview.

    Time frame: Last 3 weeks of active treatment phase (weeks 4-6)

  2. Pain intensity

    Average pain intensity is assessed during daily Ecological Momentary Assessments using the Numerical Rating Scale (NRS) . This is assessed on a scale from 0 (no pain) to 10 (most pain possible). Minimum value= 0 and maximum value=10. Higher scores indicate higher levels of pain (i.e. worse outcome). Analysis will examine average pain levels after treatment (weeks 4-6).

    Time frame: Last 3 weeks of active treatment phase (weeks 4-6)

  3. Substance use craving

    Substance use craving is measured during daily Ecological Momentary Assessments using an item validated in past work: "How strong is your urge to use substances right now? This includes marijuana, alcohol, nicotine, and other drugs." This is assessed on scale from 0 (no urge) to 10 (strongest urge ever). Minimum value= 0 and maximum value=10 and higher scores indicate higher levels of craving (i.e. worse outcomes). Analysis will examine responses to this item after treatment (weeks 4-6).

    Time frame: Last 3 weeks of active treatment phase (weeks 4-6)

  4. Abstinent days

    Abstinent days (proportion of days on which no cannabis use is reported) during the last 3 weeks (treatment weeks 4-6). The analysis will control for baseline (defined as proportion of abstinent days in the two weeks preceding the treatment).

    Time frame: Last 3 weeks of active treatment phase (weeks 4-6)

  5. Pain intereference

    Pain interference is assessed during daily Ecological Momentary Assessments using 1 item: "How much is physical pain getting in the way of doing regular daily activities right now, including eating and drinking?" This is assessed on a scale from 0 (not at all ) to 10 (extremely). Minimum value= 0 and maximum value=10. Higher scores indicate higher levels of pain interference (i.e. worse outcome). Analysis will examine ratings of pain interference after treatment (weeks 4-6).

    Time frame: Last 3 weeks of active treatment phase (weeks 4-6)

  6. Pain coping strategies

    Utilization of non-pharmacological pain coping skills is assessed during daily Ecological Momentary Assessments using a checklist of psychosocial (n=10 items) and physical coping strategies (n=10 items). Responses are binary (yes or no). The minimum value for each type of skill is 0 and the maximum value is 10. Higher scores reflect higher utilization of these skills (i.e. better outcomes). Analysis will examine utilization of non-pharmacological pain coping skills after treatment (weeks 4-6)

    Time frame: Last 3 weeks of active treatment phase (weeks 4-6)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 6 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2026
First posted
Jul 28, 2026
StartActual
Jun 29, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07731295
Lead sponsor
Brown University
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Jun 29, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 28, 2026

Study contacts

Melissa Pielech, PhD
Contact
melissa_pielech@brown.edu
401-863-6583
Kristin Rogers, MS
Contact
kristin_rogers@brown.edu
401-863-6463

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion